6 October 2015 - - US-based specialty pharmaceutical company Osmotica Pharmaceutical Corp. has appointed Samer Kaba, M.D. as vice president, head of global clinical development and medical affairs, the company said on Tuesday. In his role, Kaba will serve as a key member of the senior leadership team at Osmotica Pharmaceutical, where he is responsible for leading the global clinical development strategy and execution for the company's medical affairs programs. Prior to joining Osmotica Pharmaceutical, Kaba was vice president of neurosciences at Medpace, chief medical officer at Camarago Pharmaceutical Services, and global head of medical affairs and product development at Premier Research Group. Prior to joining the pharmaceutical industry, Kaba held multiple academic positions at the University of Texas MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Emory University, and maintained a neurology private practice. Osmotica Pharmaceutical uses its proprietary osmotic technology platform and with strategic partners develops and commercialises pharmaceutical products. In addition to the products currently on the market, the company's pipeline includes ANDA programmes and several innovative neurology-based NDA programmes. Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.